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A NOVEL BISPECIFIC ANTIBODY FOR HER2+ BREAST CANCER: THE BEAT GBR 1302 
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While the idea of bispecific drugs was brought up over 30 years ago, the development of formats mature 
enough for the clinic remained for a long time a challenge. The whole field has been hampered by major 
problems of manufacturability (e.g. product purity and yields) and immunogenicity. With the recent arrival of 
new bispecific formats, either as antibody–like molecules (containing an Fc) or scFv fragments, at least 18 
bispecific molecules have entered clinical trials showing very promising results. The BEAT® format has 
been developed as bispecific antibodies maintaining the pharmacokinetics and the low immunogenicity of 
human IgG with excellent manufacturability properties. In brief, the molecule is asymmetric consisting of a 
Hc, a Lc and a Fc-scFv. A proprietary engineered CH3 interface mimics the natural association of the 
heterodimeric TCRα β chains driving heterodimerization of the Hc and Fc-scFv. CHO cell lines are 
generated with a volumetric productivity of several g/L and a high product purity (e.g. >90% of bispecific 
product). Based on a built-in purification approach the BEAT molecules can be purified using a standard 
DSP process with yield and purity comparable to standard mAbs. The presentation will highlight a new 
bispecific drug targeting HER2 on tumor cells and CD3 on cytotoxic T-cells: the GBR 1302-BEAT molecule. 
GBR 1302-BEAT effectively recruits cytotoxic T cells against HER2 positive breast cancer cells including the 
trastuzumab-resistant breast cancer cell line JIMT-1. It shows strong tumor cell lysis activity with a better in 
vitro potential than current HER2-targeting therapies including the ADC TDM-1. The differential killing 
efficacy both in vitro and in vivo of HER2 overexpressing (3+) and normal, HER2 (0) cells reveals a large 
therapeutic window. In addition GBR 1302 does not trigger non-specific T cell activation. The excellent 
manufacturing attributes and the pre-clinical efficacy and safety of GBR1302 justify further clinical 
development as a treatment for HER2 positive cancers. 
